Systemic mastocytosis with associated hematological neoplasm

Also known as: Aggressive Systemic Mastocytosis / Aggressive Systemic Mastocytosis (ASM) / Mastocytosis, Systemic / Systemic mastocytosis

DrugDrug NameDrug Description
DB00619ImatinibImatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
DB06595MidostaurinMidostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108]. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
DrugDrug NameTargetType
DB00619ImatinibPlatelet-derived growth factor receptor betatarget
DB00619ImatinibTyrosine-protein kinase ABL1target
DB00619ImatinibMast/stem cell growth factor receptor Kittarget
DB00619ImatinibRET proto-oncogenetarget
DB00619ImatinibHigh affinity nerve growth factor receptortarget
DB00619ImatinibMacrophage colony-stimulating factor 1 receptortarget
DB00619ImatinibPlatelet-derived growth factor receptor alphatarget
DB00619ImatinibEpithelial discoidin domain-containing receptor 1target
DB00619ImatinibCytochrome P450 3A4enzyme
DB00619ImatinibBCR/ABL fusion protein isoform X9target
DB00619ImatinibCytochrome P450 1A2enzyme
DB00619ImatinibCytochrome P450 2D6enzyme
DB00619ImatinibCytochrome P450 2C9enzyme
DB00619ImatinibCytochrome P450 2C19enzyme
DB00619ImatinibCytochrome P450 3A5enzyme
DB00619ImatinibCytochrome P450 3A7enzyme
DB00619ImatinibSolute carrier family 22 member 1transporter
DB00619ImatinibMultidrug resistance protein 1transporter
DB00619ImatinibSolute carrier family 22 member 2transporter
DB00619ImatinibATP-binding cassette sub-family G member 2transporter
DB00619ImatinibATP-binding cassette sub-family A member 3transporter
DB00619ImatinibProstaglandin G/H synthase 1enzyme
DB00619ImatinibSerum albumincarrier
DB00619ImatinibAlpha-1-acid glycoprotein 1carrier
DB06595MidostaurinProtein kinase C alpha typetarget
DB06595MidostaurinVascular endothelial growth factor receptor 2target
DB06595MidostaurinMast/stem cell growth factor receptor Kittarget
DB06595MidostaurinPlatelet-derived growth factor receptor alphatarget
DB06595MidostaurinPlatelet-derived growth factor receptor betatarget
DB06595MidostaurinReceptor-type tyrosine-protein kinase FLT3target
DB06595MidostaurinCytochrome p450 3A subfamilyenzyme
DB06595MidostaurinCytochrome P450 1A2enzyme
DB06595MidostaurinCytochrome P450 2B6enzyme
DB06595MidostaurinCytochrome P450 2C8enzyme
DB06595MidostaurinCytochrome P450 2C9enzyme
DB06595MidostaurinCytochrome P450 2C19enzyme
DB06595MidostaurinCytochrome P450 2D6enzyme
DB06595MidostaurinCytochrome P450 2E1enzyme
DB06595MidostaurinCytochrome P450 3A4enzyme
DB06595MidostaurinCytochrome P450 3A5enzyme
DB06595MidostaurinCytochrome P450 3A7enzyme
DB06595MidostaurinCytochrome P450 3A43enzyme
DrugDrug NamePhaseStatusCount
DB08870Brentuximab vedotin2Recruiting1
DB09053Ibrutinib2Recruiting1